Skip to content

Regeneron Pharmaceuticals, Inc.

REGN· NasdaqCore metricsCIK 872589

Pharmaceutical preparations553 peers

Last sale
Oct 30, 2026 · +13.52%
Market cap
$95.96B
103.45M shares
Filings
1,070
$5.12B
Q3 2026+1.0% FY25 yoy
$1.95B
Q3 2026+2.1% FY25 yoy
$2.05B
Q3 2026−10.3% FY25 yoy
$2.90B
Q3 2026derived+11.3% FY25 yoy
$18.45
Q3 2026+8.2% FY25 yoy
$3.66B
Q3 2026+25.3% FY25 yoy
$95.96B
19.9×
5.7×
2.9×
3.99%
0.40%

Twelve months to Sep 30, 2026 · derived

Price

$927.63+42.20%+$275.28past year
Oct 30, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$14.34BFY 2025
$16.07B0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$14,342,900,000reported
FY 20242024-12-31$14,202,000,000reported
FY 20232023-12-31$13,117,200,000reported
FY 20222022-12-31$12,172,900,000reported
FY 20212021-12-31$16,071,700,000reported
FY 20202020-12-31$8,497,100,000reported
FY 20192019-12-31$6,557,600,000 revisedreported
FY 20182018-12-31$5,145,600,000 revisedreported
FY 20172017-12-31$5,872,200,000reported
FY 20162016-12-31$4,860,400,000reported
FY 20152015-12-31$4,103,728,000reported
FY 20142014-12-31$2,819,557,000reported

Capital returns

Dividends and buybacks · FY2016 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025$370.30M$3.44B$3.81B———93.3%
FY2024$0.00$2.60B$2.60B———71.0%
FY2023$0.00$2.24B$2.24B———57.7%
FY2022—$2.08B$2.08B———47.1%
FY2021—$1.65B$1.65B———25.2%

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018Net product sales · FY2018 · $4.11BFY2019Net product sales · FY2019 · $4.83BOther revenue · FY2019 · $174.00MFY2020Collaboration revenue · FY2020 · $1.19BNet product sales · FY2020 · $5.57BOther revenue · FY2020 · $557.00MSanofi collaboration revenue · FY2020 · $1.19BFY2021Collaboration revenue · FY2021 · $3.67BNet product sales · FY2021 · $12.12BLibtayo · FY2021 · $306.30MOther revenue · FY2021 · $281.20MSanofi collaboration revenue · FY2021 · $1.90BFY2022Collaboration revenue · FY2022 · $4.91BNet product sales · FY2022 · $6.89BLibtayo · FY2022 · $447.50MOther revenue · FY2022 · $365.10MSanofi collaboration revenue · FY2022 · $2.86BFY2023Collaboration revenue · FY2023 · $5.50BNet product sales · FY2023 · $7.08BLibtayo · FY2023 · $863.10MOther revenue · FY2023 · $536.10MFY2024Collaboration revenue · FY2024 · $6.06BNet product sales · FY2024 · $7.63BLibtayo · FY2024 · $1.22BOther revenue · FY2024 · $515.00MFY2025Collaboration revenue · FY2025 · $7.33BNet product sales · FY2025 · $6.31BLibtayo · FY2025 · $1.45BOther revenue · FY2025 · $702.60MOther products · FY2025 · $10.10M
LineFY2025ShareChange
Collaboration revenue$7.33B51%+21.0%
Net product sales$6.31B44%−17.3%
Libtayo$1.45B10%+19.3%
Other revenue$702.60M4.9%+36.4%
Other products$10.10M0.1%—
Sanofi collaboration revenue———
Total$14.34B

From the 10-K filed Feb 4, 2026REGN

Pharmaceutical preparations

Regeneron Pharmaceuticals, Inc. is the 11th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Regeneron Pharmaceuticals, Inc. · CIK 872589 · Engraved from SEC EDGAR